• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    Elanco Animal Health Incorporated filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

    2/25/25 7:05:31 AM ET
    $ELAN
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $ELAN alert in real time by email
    elan-20250225
    FALSE000173910400017391042025-02-252025-02-25

    UNITED STATES
    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549
    _______________________
    Form 8-K
    _______________________
    CURRENT REPORT
    Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

    Date of Report (Date of earliest event reported): February 25, 2025

    Elanco Animal Health Incorporated
    (Exact name of Registrant as specified in its charter)
    INDIANA
    001-38661 82-5497352
    (State or other jurisdiction of(Commission File (I.R.S. Employer
    incorporation)Number) Identification No.)
    2500 INNOVATION WAY
     46140
    GREENFIELD, INDIANA
     (Zip Code)
    (Address of principal executive offices) 
    Registrant’s telephone number, including area code: (877) 352-6261

    Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
    ☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
    ☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
    ☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
    ☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
    Securities registered pursuant to Section 12(b) of the Act:
    Title of each classTrading Symbol(s)Name of each exchange on which registered
    Common stock, no par valueELANNew York Stock Exchange
    Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
    ☐ Emerging growth company
    If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐



    Item 2.02    Results of Operations or Financial Condition.
    Attached as Exhibit 99.1 and incorporated by reference into this Item 2.02 is a copy of the press release, dated February 25, 2025, announcing the results of operations for the full year and fiscal quarter ended December 31, 2024, and guidance for the full year and first quarter of 2025, for Elanco Animal Health Incorporated.
    The information in this Item 2.02, including Exhibit 99.1 attached hereto, is being furnished and shall not be deemed “filed” for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended (“Exchange Act”), or otherwise subject to the liabilities of that Section and shall not be incorporated by reference into any registration statement or other document pursuant to the Securities Act of 1933, as amended, or the Exchange Act, except as otherwise expressly stated in such filing.

    Item 9.01    Financial Statements and Exhibits.
    (d) Exhibits

    Exhibit NumberDescription
    99.1
    Press Release issued by Elanco Animal Health Incorporated dated February 25, 2025
    104.1Cover Page Interactive Data File (embedded within the Inline XBRL document)


    Signatures
    Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

    ELANCO ANIMAL HEALTH INCORPORATED
    Date:February 25, 2025/s/ Todd S. Young
    Todd S. Young
    Executive Vice President and Chief Financial Officer

    Get the next $ELAN alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $ELAN

    DatePrice TargetRatingAnalyst
    12/9/2024$18.00Buy
    UBS
    12/2/2024$14.00Market Perform
    Leerink Partners
    9/19/2024$17.00 → $15.00Overweight → Equal-Weight
    Morgan Stanley
    1/5/2024$13.00 → $20.00Hold → Buy
    Stifel
    12/19/2023$17.00Buy
    Jefferies
    12/15/2023$16.00Equal-Weight → Overweight
    Morgan Stanley
    12/7/2023$18.00Outperform
    Exane BNP Paribas
    4/20/2023$14.00Equal Weight → Overweight
    Barclays
    More analyst ratings